Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for secondary erythromelalgia.
7 publications have been identified in PubMed for secondary erythromelalgia. Research spans Case Report / Case Series (86%) and Review / Meta-Analysis (14%).
Cohen K (2026). [PMID: 41084402](https://pubmed.ncbi.nlm.nih.gov/41084402/). *Pediatr Dermatol*. [Case Report / Case Series]
Kudrjavtseva AA (2026). [PMID: 41705614](https://pubmed.ncbi.nlm.nih.gov/41705614/). *Ter Arkh*. [Case Report / Case Series]
Parry SM (2025). [PMID: 40019187](https://pubmed.ncbi.nlm.nih.gov/40019187/). *A A Pract*. [Case Report / Case Series]
Hoxha D (2025). [PMID: 40612082](https://pubmed.ncbi.nlm.nih.gov/40612082/). *J Brown Hosp Med*. [Case Report / Case Series]
Zhang H (2025). [PMID: 41034711](https://pubmed.ncbi.nlm.nih.gov/41034711/). *J Int Med Res*. [Case Report / Case Series]
Magro C (2025). [PMID: 39846717](https://pubmed.ncbi.nlm.nih.gov/39846717/). *Am J Dermatopathol*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 10:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Bolzon A (2024). [PMID: 38800043](https://pubmed.ncbi.nlm.nih.gov/38800043/). *Exp Ther Med*. [Case Report / Case Series]
AI-curated news mentioning secondary erythromelalgia
Updated Aug 3, 2026
Recent research identifies gene variants linked to pediatric-onset erythromelalgia, enhancing understanding of this rare condition. The study employs Mendelian and rare-variant association analyses to uncover genetic factors contributing to the disease.
The EMA has granted orphan drug designation to ACD440 for the treatment of erythromelalgia, providing regulatory support for this rare condition. This designation may facilitate faster development and access for patients suffering from this painful disorder.